knowledge -WSS

knowledge

author：fashion 2025-09-03 05:34:31 - browse：55886

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Stigma and the return of syphilis

explore

Wikipedia

WSS

Use wet bulb globe temperature, not heat index, to protect workers

Childbirth

What nurses really want: sufficient staffing for patient care

How to improve immunocompromised access to mAb treatments

Apple Watch's A

Dairy farmers resist CDC push for PPE against bird flu virus

focus

knowledge

knowledge

Apple is now the first public company to be valued at $3 trillion

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Psychedelics group wrestles with new pharma identity

Stigma and the return of syphilis

Affirmative action in medical school literally saved lives

iTeos Therapeutics debuts first data on TIGIT

ChatGPT in medicine: STAT answers readers' burning questions

Focused ultrasound for uterine fibroids: an uphill battle

Novavax promises a turnaround & Lilly roils the obesity market

Use wet bulb globe temperature, not heat index, to protect workers

hotspot

Researchers on aging grapple with how to calculate biological age

Biohaven protein

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Report: NIH

focus

explore

Wikipedia

focus